Catalyst

Slingshot members are tracking this event:

Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV PDUFA set to February 12, 2018

Source Link:
http://www.gilead.com/news/press-releases/2017/8/gilead-announces-us-fda-priority-review-designation-for-fixeddose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-treatment-of-hiv

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
GILD Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 07, 2018
Occurred Source:
http://www.gilead.com/news/press-releases/2018/2/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv1-infection
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Bictegravir, Emtricitabine, Tenofovir Alafenamide
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.